Want to see INMB full AI Analyst Report?
Top Page
Inmune Bio
(NASDAQ:INMB)
Select Model
Select Model
Rating:54Neutral
Price Target:
$1.50
▼(-1.96% Downside)
Action:Reiterated
Date:07/01/26
The score is held back primarily by weak financial performance (no TTM revenue, persistent losses, and ongoing cash burn with reliance on funding). Offsetting factors include constructive price trend above key moving averages and generally positive development/regulatory updates (earnings call and corporate events), though valuation remains hard to justify on earnings due to losses and financing/dilution risk persists.
Positive Factors
Regulatory alignment for CORDStrom/Ebstrocel
MHRA alignment on chemistry, manufacturing, controls and evidence framework materially de-risks the UK conditional marketing pathway for Ebstrocel. This reduces regulatory uncertainty, clarifies pivotal endpoints and supports coordinated EU/US filings, improving the chance of eventual commercialization and partnerability over the next 2–6 months.
Negative Factors
Pre-commercial with zero TTM revenue and large losses
INMB remains pre-revenue and deeply unprofitable, with a TTM net loss near $42M and negative gross profit. Absent successful approvals, partnerships or licensing, ongoing losses erode equity and necessitate external funding, increasing execution risk and constraining long-term investment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment for CORDStrom/Ebstrocel
MHRA alignment on chemistry, manufacturing, controls and evidence framework materially de-risks the UK conditional marketing pathway for Ebstrocel. This reduces regulatory uncertainty, clarifies pivotal endpoints and supports coordinated EU/US filings, improving the chance of eventual commercialization and partnerability over the next 2–6 months.
Read all positive factors
Inmune Bio (INMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.55M
Dividend YieldN/A
Average Volume (3M)440.58K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth-100.00%
EPS Growth13.12%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,585,258
10 Day Avg. Volume255,207
30 Day Avg. Volume440,584
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-136.23
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$7.50Price Target Upside390.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Inmune Bio Business Overview & Revenue Model
Company Description
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing ...
How the Company Makes Money
null...
Inmune Bio Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.Positive Updates
CORDStrom regulatory progress (PIP and MAA preparation)
Submitted Pediatric Investigation Plan (PIP) to U.K. regulator; approved for rapid assessment with response received April 9 and no substantial issues raised. Marketing Authorization Application (MAA) documentation across five sections is well underway; company expects to submit to MHRA in early Q3 and is targeting parallel EMA/FDA filings to meet the previously stated end-of-year filing timeline.
Negative Updates
Minor regulatory delays shifting MHRA timing
Management disclosed 'some minor regulatory delays' that moved the planned MHRA submission to early Q3 rather than earlier in the year, introducing schedule risk to the previously communicated timeline.
Read all updates
Q1-2026 Updates
Positive
Negative
CORDStrom regulatory progress (PIP and MAA preparation)
Submitted Pediatric Investigation Plan (PIP) to U.K. regulator; approved for rapid assessment with response received April 9 and no substantial issues raised. Marketing Authorization Application (MAA) documentation across five sections is well underway; company expects to submit to MHRA in early Q3 and is targeting parallel EMA/FDA filings to meet the previously stated end-of-year filing timeline.
Read all positive updates
Company Guidance
Management guided that CORDStrom remains on track for regulatory filings, expecting to submit to the U.K. MHRA in early Q3 2026 and to pursue parallel EMA/FDA submissions (TMC Pharma retained) with an end‑of‑year 2026 filing target and commercial manufacturing/supply planned for 2027; manufacturing validation has begun (first of 3 process‑validation runs started on time, two remaining scheduled), the pediatric investigation plan received a rapid assessment with regulator response on April 9 and a final response due shortly, and an amended material transfer agreement with Anthony Nolan to secure umbilical cord supply was signed; financial guidance/metrics included Q1 2026 net loss of ~ $5.4M (vs. ~$9.7M Q1 2025), R&D spend of ~ $3.6M (vs. ~$7.6M), G&A of ~ $2.2M (vs. ~$2.3M), cash and cash equivalents of ~ $21.4M as of March 31, 2026 with runway into Q1 2027, and ~26.6M shares outstanding as of May 7, 2026.Inmune Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K |
| Gross Profit | -108.00K | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K |
| EBITDA | -25.09M | -45.85M | -41.53M | -267.00K | -1.35M | -1.19M |
| Net Income | -41.60M | -45.93M | -42.08M | -30.01M | -27.30M | -30.34M |
Balance Sheet | ||||||
| Total Assets | 25.82M | 32.35M | 39.56M | 57.00M | 81.80M | 99.94M |
| Cash, Cash Equivalents and Short-Term Investments | 21.36M | 24.75M | 20.92M | 35.85M | 52.15M | 74.81M |
| Total Debt | 1.51M | 1.03M | 384.00K | 10.44M | 15.31M | 15.23M |
| Total Liabilities | 6.19M | 8.83M | 7.46M | 18.86M | 21.69M | 19.72M |
| Stockholders Equity | 19.62M | 23.52M | 32.10M | 38.14M | 60.10M | 80.22M |
Cash Flow | ||||||
| Free Cash Flow | -20.78M | -23.62M | -33.36M | -11.98M | -22.69M | -43.50M |
| Operating Cash Flow | -19.17M | -22.58M | -33.36M | -11.98M | -22.69M | -28.50M |
| Investing Cash Flow | -1.04M | -1.04M | 0.00 | 0.00 | 0.00 | -15.00M |
| Financing Cash Flow | 22.34M | 27.61M | 18.21M | -4.22M | 729.00K | 96.36M |
Inmune Bio Technical Analysis
Positive
1.53
Price Trends
1.41
Positive
1.36
Positive
1.56
Positive
Market Momentum
0.04
Negative
64.54
Neutral
71.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INMB, the sentiment is Positive. The current price of 1.53 is above the 20-day moving average (MA) of 1.36, above the 50-day MA of 1.41, and below the 200-day MA of 1.56, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 64.54 is Neutral, neither overbought nor oversold. The STOCH value of 71.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INMB.
Inmune Bio Risk Analysis
Inmune Bio disclosed 59 risk factors in its most recent earnings report. Inmune Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inmune Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $132.56M | -5.73 | -98.30% | ― | 309.60% | 72.33% | |
55 Neutral | $221.42M | -0.66 | 73.11% | ― | 6.33% | -102.63% | |
54 Neutral | $38.55M | ― | -170.86% | ― | -100.00% | 13.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $50.24M | -3.93 | -53.43% | ― | -100.00% | 63.20% | |
44 Neutral | $17.31M | -0.17 | 411.46% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
INMB
Inmune Bio
1.63
-0.73
-30.93%
VERU
Veru
3.13
-2.71
-46.40%
KPTI
Karyopharm Therapeutics
9.77
5.16
111.93%
CUE
Cue Biopharma
31.56
10.80
52.03%
CELU
Celularity
0.60
-1.43
-70.59%
JUNS
Jupiter Neurosciences, Inc.
0.21
-0.98
-82.02%
Inmune Bio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
INmune Bio Executes Warrant Inducement and Extension Agreement
Positive
Jul 1, 2026
On June 30, 2026, INmune Bio entered into a warrant inducement agreement and a second amendment with certain holders of common stock purchase warrants issued in April 2024. The company offered these investors the chance to exercise 50% of their wa...
Business Operations and StrategyRegulatory Filings and Compliance
INmune Bio Advances Ebstrocel Toward UK Conditional Approval
Positive
Jun 23, 2026
On June 23, 2026, INmune Bio said the UK Medicines Healthcare products Regulatory Agency had provided written minutes from a May 12 pre-Marketing Authorization Application meeting that confirmed alignment on chemistry, manufacturing and controls,...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan
Positive
Jun 17, 2026
At its Annual Meeting held after April 20, 2026, Inmune Bio shareholders elected five directors—David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda and Marcia Allen—to serve until the next shareholder meeting, reflecting continued s...
Business Operations and Strategy
INmune Bio reports positive Phase 2 MRI results
Positive
Jun 2, 2026
On June 2, 2026, INmune Bio reported statistically significant chi-separation MRI results from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease, including mild cognitive impairment and mild dementia. After 24 ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
INmune Bio Receives FDA Fast Track for XPro
Positive
May 14, 2026
On May 14, 2026, INmune Bio Inc. announced that the U.S. Food and Drug Administration granted Fast Track designation to XPro™ (pegipanermin), its first-in-class selective soluble TNF inhibitor, for the treatment of early Alzheimer’s di...
Business Operations and Strategy
INmune Bio Expands Cord Tissue License for CORDStrom Platform
Positive
May 5, 2026
On April 29, 2026, INmune Bio Inc. and its UK subsidiary INmune Bio International entered into an amended and restated material transfer and license agreement with UK charity Anthony Nolan, formalizing INmune Bio as a party and making it jointly l...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.